Core Viewpoint - The article highlights the significant performance growth of China Shipbuilding and China State Shipbuilding Corporation, driven by their focus on core business operations and effective management strategies, amidst a major merger and acquisition process [1][4][5]. Group 1: Performance Forecast - China Shipbuilding expects a net profit attributable to shareholders of 2.8 billion to 3.1 billion yuan for the first half of 2025, representing a year-on-year growth of 98.25% to 119.49% [4]. - China State Shipbuilding anticipates a net profit of 1.5 billion to 1.8 billion yuan for the same period, with a year-on-year increase of 181.73% to 283.08% [4]. Group 2: Reasons for Growth - China Shipbuilding attributes its performance increase to a focus on core responsibilities, ensuring production safety, enhancing production efficiency, and optimizing order structures [4]. - China State Shipbuilding emphasizes its ability to leverage industry trends, improve management practices, and increase the quantity of delivered civil ship products, leading to significant revenue growth [4][5]. Group 3: Merger and Acquisition Impact - The merger between China Shipbuilding and China State Shipbuilding is expected to create a leading entity in the shipbuilding industry, enhancing economic, functional, and strategic value [5]. - The merger has received key approvals, with plans to integrate high-quality assets from China State Shipbuilding, which will strengthen the overall market position and operational capabilities of the combined entity [5].

Core Viewpoint - The article emphasizes the Chinese government's commitment to enhancing pharmaceutical innovation and development, particularly in the areas of innovative drugs and medical devices, to support public health and the construction of a healthy China [1][2]. Group 1: Government Initiatives - Liu Guozhong, a member of the Political Bureau of the CPC Central Committee, highlighted the importance of strengthening collaborative efforts and policy implementation in the pharmaceutical sector to boost innovation and development [2]. - The government aims to enhance the integration of industry, academia, and research institutions to improve the level of pharmaceutical technology innovation and achieve breakthroughs in drug, vaccine, and medical device development [2][4]. - The State Drug Administration (NMPA) is working on optimizing the clinical trial review and approval process for innovative drugs, aiming to complete reviews within 30 working days for eligible applications [3]. Group 2: Regulatory Framework - The NMPA has proposed measures to support high-end medical device innovation, including optimizing special approval procedures and improving classification and naming principles [4]. - The upcoming measures will focus on enhancing the regulatory framework for high-end medical devices, which include medical robots, advanced imaging equipment, and AI medical devices [4][5]. - The government is committed to creating a favorable development environment by strengthening policy guarantees and promoting international cooperation in pharmaceutical technology [2][4]. Group 3: Industry Development - The article notes that China's pharmaceutical innovation has shown positive trends, with significant improvements in research and development capabilities, market competitiveness, and innovation vitality [2]. - The integration of new technologies such as artificial intelligence and big data is expected to accelerate the construction of health databases and improve the efficiency of pharmaceutical research and medical services [2][4]. - The measures introduced by the NMPA are seen as crucial for supporting major innovations in high-end medical devices and meeting the health needs of the population [4][5].

上天天基金APP搜索【777】注册即可 领500元券包，优选基金10元起投！限量发放！先到 先得！ 7 月11日早盘，A股三大指数集体高开。截至发稿，沪指涨0.76%，深成指涨0.54%，创业 板指涨0.72%。 板块上来看，大金融板块震荡拉升，券商、保险、银行等板块走强，创新药板块再度活跃； 而教育、零售、能源设备等板块震荡走低。 港股方面，三大指数均涨超1%，蔚来、阿里巴巴、阿里健康等涨幅居前。 | 整体市场 它 | | | | --- | --- | --- | | 恒生指数 | 恒生国企 | 恒生科技 | | 24404.33 | 8799.11 | 5302.50 | | +375.96 +1.56% | +130.85 +1.51% | +85.90 +1.65% | | 恒指期货 | 港股通50 | 恒生生物科技 | | 24419 | 3645.09 | 13922.77 | | +396 +1.65% | +56.48 +1.57% | +196.71 +1.43% | 此外，国盛金控发布的2025年半年度业绩预告显示，预计上半年归属于上市公司股东的净利 润为1.5亿元至2.2亿元，同比增长 ...

当地时间7月10日，美股三大指数均小幅收涨。 纳斯达克指数、标普500指数创历史新高。 （图片来源：东方财富APP，统计截至2025/7/10，不作投资推荐） 美国大型科技股涨跌不一。截至收盘，万得美国科技七巨头指数涨0.42%。成分股中，特斯 拉涨超4.7%，股价升至300美元上方。 消息面上，特斯拉CEO埃隆·马斯克当地时间周四在社交平台透露，xAI的聊天机器人"Grok 4"将最晚于下周登陆特斯拉汽车。此外，马斯克当地时间周三透露，公司自动驾驶出租车服 务有望在"一两个月内"扩展至旧金山湾区，具体时间需视监管审批进度而定。 | 六米 | 成分 资讯 | 相关基金 | | | --- | --- | --- | --- | | 名称 | 现价 | 涨跌幅 ◆ | | | 特斯拉(TESLA) | 309.870 | 4.73% | 13.99 | | TSLA.O | | | | | 英伟达(NVIDIA) NVDA.O | 164.100 | 0.75% | 1.22 | | 苹果(APPLE) AAPL.O | 212.410 | 0.60% | 1.27 | | 谷歌(ALPHABET)· | 17 ...

据央视新闻消息，当地时间7月10日，美国总统特朗普宣布，将自8月1日起，对自加拿大进口的商品 征收35%关税。 加元应声下跌。美元/加元一度上涨0.6%，至1.3731；美元兑G10货币悉数上涨，美元即期指数上涨 0.2%。澳元/美元下跌0.4%至0.6561。新西兰元/美元下跌0.4%至0.6014。 美股股指期货扩大跌幅，其中标普500指数期货跌0.5%，纳指期货下跌0.6%。 此前，特朗普表示美国将自2025年8月1日起对所有巴西产品征收50%的关税。巴西副总统兼发展、工 业、贸易和服务部长热拉尔多·阿尔克明当天表示，特朗普宣布对巴西商品征收新关税是不公平的。他回 应道, "我看不出有任何理由要对巴西提高关税。巴西不是美国的问题，这一点需要强调。美国确实有贸易 逆差，但对巴西是顺差。在美国对我们出口的产品中，十中有八都是零关税的，不需要缴税。"他进一步 表示，这项针对巴西的措施是不公平的，也会对美国自身经济造成损害，因为在贸易领域是存在一体化 的。 免责声明 文章封面图来源于AI，以上观点来自相关机构，不代表天天基金的观点，不对观点的准确性 和完整性做任何保证。收益率数据仅供参考，过往业绩和走势风格不预 ...

Core Viewpoints - The investment approach should resemble that of a farmer, focusing on long-term cultivation rather than short-term hunting, which is more challenging [1] - Price fluctuations can be severe, but the intrinsic value of companies, especially excellent ones, remains stable, continuously generating substantial free cash flow [2] - There is growing optimism among global investors regarding China's long-term development potential [3] - The key to investment lies in objectively assessing true value and leveraging market fluctuations rather than being defeated by them [4] - Long-term, patient investment is more successful than attempting to time the market [5] Economic and Market Cycles - The dialogue between Chen Guangming and Howard Marks covered economic cycles, global market volatility, and investment opportunities in China [2] U.S. Market Insights - Howard Marks believes the U.S. economy remains strong, with trade policies being the main uncertainty affecting market reactions [6] - The U.S. stock market accounts for 50% of global market capitalization, while its GDP is only about 25% of the global total, indicating high valuations [4] Market Volatility - Chen Guangming noted that while there were significant fluctuations in China's market in April, these were more reflective of short-term risk preferences rather than long-term fundamentals [10] Chinese Technological Innovation - The emergence of DeepSeek has shifted investor sentiment positively towards China's market, indicating that China is competitive in technology sectors like AI [12] - Howard Marks emphasized that the U.S. does not monopolize technological advancement, and competition from countries like China is significant [12] - Chen Guangming expressed optimism about investment opportunities across various sectors in China, highlighting the country's innovative capabilities and efficient supply chains [16][17] Value Investing Practices - Chen Guangming explained that the principles of value investing are consistent globally, focusing on buying below intrinsic value for returns [19] - In China, the stability and sustainability of intrinsic value may be weaker, making assessments more challenging [20] - The volatility in emerging markets like China can lead to greater investment opportunities if value investors can accurately assess intrinsic value [20]

Core Viewpoint - There is a significant trend of foreign capital inflow into Chinese companies, as evidenced by multiple global emerging market funds increasing their positions in Chinese stocks, particularly in the pharmaceutical sector [1][3]. Fund Activity - Invesco Developing Markets Fund increased its holdings in Hengrui Medicine by 100%, with a total market value of HKD 1.86 million after the increase [3]. - JPM China A-Share Opportunities Fund raised its stake in Hengrui Medicine by 18.49% [6]. - Allianz China A Shares Fund also increased its position in Hengrui Medicine by 8.47% [8]. Market Insights - The fund manager of Invesco, Justin Leverenz, expressed optimism about the Chinese pharmaceutical industry, noting that China has transitioned from a follower to a leader in drug development over the past five years [4]. - The Chinese biotechnology sector is still in its early stages, with significant potential for growth as companies have yet to fully engage in value-creating activities such as late-stage global clinical development and commercialization [4]. Performance Metrics - As of the end of May, the Invesco fund had a total size of approximately USD 14.1 billion (CNY 1012.41 billion) [3]. - The Allianz fund had a total size of USD 2.3 billion [8]. - The JPM fund had a total size of USD 2.8 billion [7]. Foreign Investment Sentiment - Temasek, Singapore's state investment firm, reported a net asset value of USD 340 billion, reflecting an 11.6% year-on-year growth, and continues to view China positively for long-term prospects [13].

Core Viewpoint - The article highlights the recent performance of the Shanghai Composite Index, which briefly surpassed 3500 points on July 9, 2024, before closing at 3493.05 points, a decrease of 0.13%. This marks the first time the index has crossed this threshold in approximately eight months [1]. Industry Performance - The multi-financial sector played a significant role in the index's performance, achieving a 2.75% increase on July 9, 2024, and leading the industry in gains over the past three trading days with a total increase of 7.65%. Notable companies in this sector include Yuexiu Capital and Nanhua Futures, both of which reached their daily limit up [1]. - Multi-financial companies typically engage in activities outside of traditional banking and securities, including futures, leasing, and trust services. Key players in this sector include Yong'an Futures, Nanhua Futures, Bohai Leasing, and various financial holding companies [1]. Market Drivers - The recent activity in the multi-financial sector is attributed to a favorable macroeconomic environment and accelerated financial innovations, such as stablecoins. The trend towards the compliance of virtual assets is expected to activate and reshape the entire non-bank financial industry chain, with a collaborative ecosystem for digital asset issuance, circulation, management, and application rapidly taking shape [1].

Core Viewpoint - The entry of Jay Chou into Douyin has led to significant stock movements in related companies, particularly in Hong Kong and A-shares, indicating a strong market reaction to celebrity endorsements and partnerships [1][2]. Group 1: Stock Movements - On July 9, stocks related to Jay Chou experienced a collective surge, with Hong Kong's Giant Legend rising over 165% at one point and closing up 94.38%, with a trading volume exceeding 11.5 billion HKD [1]. - In the A-share market, Fengshang Culture hit the daily limit up, while Zhizhong Home and Meibang Clothing also reached their daily limit, and Haoyang Shares increased by nearly 6% [1]. Group 2: Jay Chou's Douyin Account - Jay Chou officially joined Douyin on July 9, using the name "Zhou Tongxue" and identifying as a singer, with his official avatar being his unique two-dimensional IP image [1]. - As of 5 PM on the same day, Jay Chou's Douyin account had not posted any content but had already garnered 5.35 million followers [1]. Group 3: Company Partnerships - Giant Legend, which is closely tied to Jay Chou, reported an IP creation and operation revenue of 314 million CNY in 2024, primarily from the outdoor interactive variety show "Zhou You Ji 2" and a music talk show featuring Yu Chengqing [1]. - Other listed companies collaborating with Jay Chou include Zhizhong Home, Aima Technology, and China Mobile, with Fengshang Culture involved in planning his 2025 "Carnival" tour and Haoyang Shares providing LED screens for his concerts [2].

Group 1 - The "anti-involution" policy has become a hot topic in the stock and commodity markets, with various industries responding and institutions releasing related research reports [1] - Tianfeng Securities suggests that the "anti-involution" trend may develop in three phases: initial expectations catalyzed by policy, followed by rising prices of resource products, and finally, a prolonged period of high prices for these resources [1] - CITIC Securities identifies three key differences between the current "anti-involution" and the supply-side reform of 2015-2016, including broader industry coverage, better operating conditions for upstream enterprises, and a higher proportion of private enterprises in emerging industries [1] Group 2 - Zhejiang Merchants Fund focuses on two major industrial issues: structural contradictions in capacity and disruptions to fair competition, particularly in the new energy vehicle and photovoltaic sectors, where prices have dropped significantly [2] - Dongwu Securities highlights that the "anti-involution" policy will have a more pronounced effect on correcting vicious competition and benefiting emerging industries, particularly in sectors with high state-owned enterprise representation [2] - Specific sectors to watch include the photovoltaic industry chain, traditional industries facing overcapacity like steel and cement, and emerging non-manufacturing sectors such as e-commerce [2] Group 3 - Huachuang Securities identifies potential beneficiary industries of the "anti-involution" policy based on factors like state-owned enterprise representation, industry concentration, price elasticity, taxation, and employment [3] - Industries likely to benefit include coal mining, coke, ordinary steel, energy metals, glass fiber, steel raw materials, precious metals, and the hospitality sector [3]